The Safety Profile of Amivantamab and Lazertinib in EGFR-Mutant NSCLC
June 6th 2021Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.
Amivantamab Plus Lazertinib Combo Shows Good Results in EGFR+ NSCLC
November 10th 2020Alexander Spira, MD, PhD, discusses the phase 1 CHRYSALIS trial of amivantamab plus lazertinib in 2 EGFR-mutant non–small cell lung cancer patient populations, which include patients with relapsed/refractory and those who are treatment-naive.